{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T12:14:48Z","timestamp":1792844088864,"version":"4.5.0"},"reference-count":112,"publisher":"Frontiers Media SA","content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"DOI":"10.3389\/fimmu.2017.01401","type":"journal-article","created":{"date-parts":[[2017,10,27]],"date-time":"2017-10-27T06:59:17Z","timestamp":1509087557000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":77,"title":["Current Advances in \u03b3\u03b4 T Cell-Based Tumor Immunotherapy"],"prefix":"10.3389","volume":"8","author":[{"given":"Elena","family":"Lo Presti","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriele","family":"Pizzolato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eliana","family":"Gulotta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gianfranco","family":"Cocorullo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gaspare","family":"Gulotta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Dieli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Serena","family":"Meraviglia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2017,10,27]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"975","DOI":"10.1146\/annurev.immunol.18.1.975","article-title":"\u03b3\u03b4 T cells: a right time and a right place for a conserved third way of protection","volume":"18","author":"Hayday","year":"2000","journal-title":"Annu Rev Immunol"},{"key":"B2","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1038\/ni.3686","article-title":"Human \u03b3\u03b4 T cells are quickly reconstituted after stem-cell transplantation and show adaptive clonal expansion in response to viral infection","volume":"18","author":"Ravens","year":"2017","journal-title":"Nat Immunol"},{"key":"B3","doi-asserted-by":"publisher","first-page":"14760","DOI":"10.1038\/ncomms14760","article-title":"Clonal selection in the human V\u03b41 T cell repertoire indicates \u03b3\u03b4 TCR-dependent adaptive immune surveillance","volume":"8","author":"Davey","year":"2017","journal-title":"Nat Commun"},{"key":"B4","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1038\/375155a0","article-title":"Natural and synthetic non-peptide antigens recognized by human \u03b3\u03b4T cells","volume":"75","author":"Tanaka","year":"1995","journal-title":"Nature"},{"key":"B5","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1016\/S0014-5793(03)00483-6","article-title":"Microbial isoprenoid biosynthesis and human \u03b3\u03b4T cell activation","volume":"544","author":"Eberl","year":"2003","journal-title":"FEBS Lett"},{"key":"B6","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1084\/jem.20021500","article-title":"Human T cell receptor \u03b3\u03b4 T cells recognize endogenous mevalonate metabolites in tumor cells","volume":"197","author":"Gober","year":"2003","journal-title":"J Exp Med"},{"key":"B7","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1182\/blood.V96.2.384","article-title":"Stimulation of \u03b3\u03b4 T cells by aminobisphosphonates and induction of anti plasma cell activity in multiple myeloma","volume":"86","author":"Kunzmann","year":"2000","journal-title":"Blood"},{"key":"B8","doi-asserted-by":"publisher","first-page":"2310","DOI":"10.1182\/blood-2003-05-1655","article-title":"Induction of \u03b3\u03b4 T-lymphocyte effector functions by bisphosphonate zoledronic acid in cancer patients in vivo","volume":"102","author":"Dieli","year":"2003","journal-title":"Blood"},{"key":"B9","doi-asserted-by":"publisher","first-page":"8118","DOI":"10.4049\/jimmunol.0900101","article-title":"Reduced expression of the mevalonate pathway enzyme farnesyl pyrophosphate synthase unveils recognition of tumor cells by V\u03b39V\u03b42 T cells","volume":"182","author":"Li","year":"2009","journal-title":"J Immunol"},{"key":"B10","doi-asserted-by":"publisher","first-page":"2414","DOI":"10.1073\/pnas.1015433108","article-title":"Crystal structure of a \u03b3\u03b4 T cell receptor specific for the human MHC class I homolog MICA","volume":"108","author":"Xu","year":"2011","journal-title":"Proc Natl Acad Sci U S A"},{"key":"B11","doi-asserted-by":"publisher","first-page":"6879","DOI":"10.1073\/pnas.96.12.6879","article-title":"Broad tumor-associated expression and recognition by tumor-derived \u03b3\u03b4 T cells of MICA and MICB","volume":"96","author":"Groh","year":"1999","journal-title":"Proc Natl Acad Sci U S A"},{"key":"B12","doi-asserted-by":"publisher","first-page":"1137","DOI":"10.1038\/ni.2713","article-title":"CD1d lipid antigen recognition by the \u03b3\u03b4 TCR","volume":"14","author":"Uldrich","year":"2013","journal-title":"Nat Immunol"},{"key":"B13","doi-asserted-by":"publisher","first-page":"1032","DOI":"10.1016\/j.immuni.2013.11.001","article-title":"Crystal structure of V\u03b41 T cell receptor in complex with CD1d sulfatide shows MHC like recognition of a self-lipid by human \u03b3\u03b4 T cells","volume":"39","author":"Luoma","year":"2013","journal-title":"Immunity"},{"key":"B14","doi-asserted-by":"publisher","first-page":"69","DOI":"10.3389\/fimmu.2013.00069","article-title":"Natural cytotoxicity receptors: broader expression patterns and functions in innate and adaptive immune cells","volume":"4","author":"Hudspeth","year":"2013","journal-title":"Front Immunol"},{"key":"B15","doi-asserted-by":"publisher","first-page":"30","DOI":"10.4049\/jimmunol.1300121","article-title":"CD1d restriction and Th1\/Th2\/Th17 cytokine secretion by human V\u03b43 T cells","volume":"191","author":"Mangan","year":"2013","journal-title":"J Immunol"},{"key":"B16","doi-asserted-by":"publisher","first-page":"2269","DOI":"10.1182\/blood-2012-05-430470","article-title":"Key implication of CD277\/butyrophilin-3 (BTN3A) in cellular stress sensing by a major human \u03b3\u03b4 T-cell subset","volume":"120","author":"Harly","year":"2012","journal-title":"Blood"},{"key":"B17","doi-asserted-by":"publisher","first-page":"908","DOI":"10.1038\/ni.2665","article-title":"Butyrophilin 3A1 binds phosphorylated antigens and stimulates human \u03b3\u03b4 T cells","volume":"14","author":"Vavassori","year":"2013","journal-title":"Nat Immunol"},{"key":"B18","doi-asserted-by":"publisher","first-page":"490","DOI":"10.1016\/j.immuni.2014.03.003","article-title":"The intracellular B30.2 domain of butyrophilin 3A1 binds phosphoantigens to mediate activation of human V\u03b39V\u03b42 T cells","volume":"40","author":"Sandstrom","year":"2014","journal-title":"Immunity"},{"key":"B19","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1084\/jem.20030235","article-title":"Differentiation of effector\/memory V\u03b42 T cells and migratory routes in lymph nodes or inflammatory sites","volume":"198","author":"Dieli","year":"2003","journal-title":"J Exp Med"},{"key":"B20","doi-asserted-by":"publisher","first-page":"1764","DOI":"10.1002\/eji.200525983","article-title":"Differential requirements for antigen or homeostatic cytokines for proliferation and differentiation of human V\u03b39V\u03b42 naive, memory and effector T cell subsets","volume":"35","author":"Caccamo","year":"2005","journal-title":"Eur J Immunol"},{"key":"B21","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1038\/cmi.2012.42","article-title":"Mechanisms underlying lineage commitment and plasticity of human \u03b3\u03b4 T cells","volume":"10","author":"Caccamo","year":"2013","journal-title":"Cell Mol Immunol"},{"key":"B22","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1016\/S0198-8859(97)00211-5","article-title":"Patterns of phosphoantigen stimulation of human V\u03b39V\u03b42 T cell clones include Th0 cytokines","volume":"58","author":"Sireci","year":"1997","journal-title":"Hum Immunol"},{"key":"B23","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1006\/cimm.2001.1850","article-title":"Differentiation of resting human peripheral blood \u03b3\u03b4 T cells toward Th1- or Th2-phenotype","volume":"212","author":"Wesch","year":"2001","journal-title":"Cell Immunol"},{"key":"B24","doi-asserted-by":"publisher","first-page":"7268","DOI":"10.4049\/jimmunol.1000600","article-title":"Cytokine requirements for the differentiation and expansion of IL-17A- and IL-22-producing human V\u03b39V\u03b42 T cells","volume":"184","author":"Ness-Schwickerath","year":"2010","journal-title":"J Immunol"},{"key":"B25","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1182\/blood-2011-01-331298","article-title":"Differentiation, phenotype and function of interleukin-17-producing human V\u03b39V\u03b42 T cells","volume":"118","author":"Caccamo","year":"2011","journal-title":"Blood"},{"key":"B26","doi-asserted-by":"publisher","first-page":"6611","DOI":"10.1182\/blood-2009-01-198028","article-title":"V\u03b41 T lymphocytes producing IFN-\u03b3 and IL-17 are expanded in HIV-1-infected patients and respond to Candida albicans","volume":"113","author":"Fenoglio","year":"2009","journal-title":"Blood"},{"key":"B27","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1002\/eji.201142017","article-title":"IL-21 enhances the potential of human \u03b3\u03b4 T cells to provide B-cell help","volume":"42","author":"Bansal","year":"2012","journal-title":"Eur J Immunol"},{"key":"B28","doi-asserted-by":"publisher","first-page":"e41940","DOI":"10.1371\/journal.pone.0041940","article-title":"IL-21 regulates the differentiation of a human \u03b3\u03b4 T cell subset equipped with B cell helper activity","volume":"7","author":"Caccamo","year":"2012","journal-title":"PLoS One"},{"key":"B29","doi-asserted-by":"publisher","first-page":"12520","DOI":"10.1073\/pnas.1607136113","article-title":"Human V\u03b42 T cells are a major source of interleukin-9","volume":"113","author":"Peters","year":"2016","journal-title":"Proc Natl Acad Sci U S A"},{"key":"B30","doi-asserted-by":"publisher","first-page":"3574","DOI":"10.4049\/jimmunol.0901334","article-title":"TGF-\u03b21 and IL-15 Induce FOXP3+ \u03b3\u03b4 regulatory T cells in the presence of antigen stimulation","volume":"183","author":"Casetti","year":"2009","journal-title":"J Immunol"},{"key":"B31","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1038\/nri3904","article-title":"\u03b3\u03b4 T cells in cancer","volume":"15","author":"Silva-Santos","year":"2015","journal-title":"Nat Rev Immunol"},{"key":"B32","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1038\/nri1842","article-title":"Adoptive immunotherapy for cancer: building on success","volume":"6","author":"Gattinoni","year":"2006","journal-title":"Nat Rev Immunol"},{"key":"B33","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/S0065-2776(06)90001-7","article-title":"Cancer immunosurveillance and immunoediting: the roles of immunity in suppressing tumor development and shaping tumor immunogenicity","volume":"90","author":"Smyth","year":"2006","journal-title":"Adv Immunol"},{"key":"B34","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1038\/nri3384","article-title":"Six-of-the-best: unique contributions of \u03b3\u03b4 T cells to immunology","volume":"13","author":"Vantourout","year":"2013","journal-title":"Nat Rev Immunol"},{"key":"B35","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1006\/clim.2002.5218","article-title":"Human \u03b3\u03b4T cells induce dendritic cell maturation","volume":"103","author":"Ismaili","year":"2002","journal-title":"Clin Immunol"},{"key":"B36","doi-asserted-by":"publisher","first-page":"252","DOI":"10.4049\/jimmunol.174.1.252","article-title":"Reciprocal activating interaction between dendritic cells and pamidronate-stimulated \u03b3\u03b4 T cells: role of CD86 and inflammatory cytokines","volume":"174","author":"Conti","year":"2005","journal-title":"J Immunol"},{"key":"B37","doi-asserted-by":"publisher","first-page":"1386","DOI":"10.4049\/jimmunol.176.3.1386","article-title":"Potentiation of antigen-stimulated V\u03b39V\u03b42 T cell cytokine production by immature dendritic cells (DC) and reciprocal effect on DC maturation","volume":"176","author":"Devilder","year":"2006","journal-title":"J Immunol"},{"key":"B38","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.1016\/S0022-2275(20)41954-6","article-title":"In vivo regulation of human leukocyte 3-hydroxy-3-methylglutaryl coenzyme A reductase: increased enzyme protein concentration and catalytic efficiency in human leukemia and lymphoma","volume":"32","author":"Harwood","year":"1991","journal-title":"J Lipid Res"},{"key":"B39","doi-asserted-by":"publisher","first-page":"1397","DOI":"10.3324\/haematol.2009.020602","article-title":"Identification of a panel of ten cell surface protein antigens associated with immunotargeting of leukemias and lymphomas by peripheral blood \u03b3\u03b4 T cells","volume":"95","author":"Gomes","year":"2010","journal-title":"Haematologica"},{"key":"B40","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1016\/S1074-7613(01)00168-6","article-title":"MICA engagement by human V\u03b39V\u03b42 T cells enhances their antigen dependent effector function","volume":"15","author":"Das","year":"2001","journal-title":"Immunity"},{"key":"B41","doi-asserted-by":"publisher","first-page":"2144","DOI":"10.4049\/jimmunol.175.4.2144","article-title":"Activation of V\u03b39V\u03b42 T cells by NKG2D","volume":"175","author":"Rincon-Orozco","year":"2005","journal-title":"J Immunol"},{"key":"B42","doi-asserted-by":"publisher","first-page":"2407","DOI":"10.1182\/blood-2009-08-237123","article-title":"The MHC class Ib protein ULBP1 is a non redundant determinant of leukemia\/lymphoma susceptibility to \u03b3\u03b4 T-cell cytotoxicity","volume":"115","author":"Lanca","year":"2010","journal-title":"Blood"},{"key":"B43","doi-asserted-by":"publisher","first-page":"1801","DOI":"10.1182\/blood-2004-01-0331","article-title":"Fc\u03b3RIII discriminates between 2 subsets of V\u03b39V\u03b42 effector cells with different responses and activation pathways","volume":"104","author":"Angelini","year":"2004","journal-title":"Blood"},{"key":"B44","doi-asserted-by":"publisher","first-page":"1082","DOI":"10.1086\/323600","article-title":"Granulysin dependent killing of intracellular and extracellular Mycobacterium tuberculosis by V\u03b39V\u03b42 T lymphocytes","volume":"184","author":"Dieli","year":"2001","journal-title":"J Infect Dis"},{"key":"B45","doi-asserted-by":"publisher","first-page":"4304","DOI":"10.4049\/jimmunol.178.7.4304","article-title":"Distinct cytokine driven responses of activated blood \u03b3\u03b4 T cells: insights into unconventional T cell pleiotropy","volume":"178","author":"Vermijlen","year":"2007","journal-title":"J Immunol"},{"key":"B46","doi-asserted-by":"publisher","first-page":"3660","DOI":"10.4049\/jimmunol.173.6.3660","article-title":"Fas-Fas ligand interactions are essential for the binding to and killing of activated macrophages by \u03b3\u03b4 T cells","volume":"173","author":"Dalton","year":"2004","journal-title":"J Immunol"},{"key":"B47","doi-asserted-by":"publisher","first-page":"e25821","DOI":"10.4161\/onci.25821","article-title":"Combining conventional chemotherapy and \u03b3\u03b4 T cell-based immunotherapy to target cancer-initiating cells","volume":"2","author":"Todaro","year":"2013","journal-title":"Oncoimmunology"},{"key":"B48","doi-asserted-by":"publisher","first-page":"7287","DOI":"10.4049\/jimmunol.0804288","article-title":"Efficient killing of human colon cancer stem cells by \u03b3\u03b4 T lymphocytes","volume":"182","author":"Todaro","year":"2009","journal-title":"J Immunol"},{"key":"B49","doi-asserted-by":"publisher","first-page":"e65145","DOI":"10.1371\/journal.pone.0065145","article-title":"Chemotherapy sensitizes colon cancer initiating cells to V\u03b39V\u03b42 T cell-mediated cytotoxicity","volume":"8","author":"Todaro","year":"2013","journal-title":"PLoS One"},{"key":"B50","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1038\/bjc.2011.189","article-title":"The prognostic influence of tumour-infiltrating lymphocytes in cancer: a systematic review with meta-analysis","volume":"105","author":"Gooden","year":"2011","journal-title":"Br J Cancer"},{"key":"B51","doi-asserted-by":"publisher","first-page":"1235","DOI":"10.2217\/imt.11.106","article-title":"Variation of tumor-infiltrating lymphocytes in human cancers: controversy on clinical significance","volume":"3","author":"Sasada","year":"2011","journal-title":"Immunotherapy"},{"key":"B52","doi-asserted-by":"publisher","first-page":"e1284723","DOI":"10.1080\/2162402X.2017.1284723","article-title":"Assessment of tumor-infiltrating TCR V\u03b39V\u03b42 \u03b3\u03b4 lymphocyte abundance by deconvolution of human cancers microarrays","volume":"6","author":"Tosolini","year":"2017","journal-title":"Oncoimmunology"},{"key":"B53","doi-asserted-by":"publisher","first-page":"938","DOI":"10.1038\/nm.3909","article-title":"The prognostic landscape of genes and infiltrating immune cells across human cancers","volume":"21","author":"Gentles","year":"2015","journal-title":"Nat Med"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2017.1347742","article-title":"Distinctive features of tumor-infiltrating \u03b3\u03b4 T lymphocytes in human colorectal cancer","author":"Meraviglia","year":"2017","journal-title":"Oncoimmunology"},{"key":"B55","first-page":"17","article-title":"Phosphoantigens and aminobisphosphonates: new leads targeting \u03b3\u03b4 T lymphocytes for cancer immunotherapy","volume":"3","author":"Belmant","year":"2006","journal-title":"Drug Discov Today"},{"key":"B56","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1359\/JBMR.0301230","article-title":"Statins prevent bisphosphonate-induced \u03b3\u03b4-T-cell proliferation and activation in vitro","volume":"19","author":"Thompson","year":"2004","journal-title":"J Bone Miner Res"},{"key":"B57","first-page":"81","article-title":"Efficacy and safety of \u03b3\u03b4 T cell-based tumor immunotherapy: a meta-analysis","volume":"28","author":"Buccheri","year":"2014","journal-title":"J Biol Regul Homeost Agents"},{"key":"B58","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1182\/blood-2002-12-3665","article-title":"\u03b3\u03b4 T cells for immune therapy of patients with lymphoid malignancies","volume":"102","author":"Wilhelm","year":"2003","journal-title":"Blood"},{"key":"B59","doi-asserted-by":"publisher","first-page":"7450","DOI":"10.1158\/0008-5472.CAN-07-0199","article-title":"Targeting human \u03b3\u03b4 T cells with zoledronate and interleukin-2 for immunotherapy of hormone-refractory prostate cancer","volume":"67","author":"Dieli","year":"2007","journal-title":"Cancer Res"},{"key":"B60","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1111\/j.1365-2249.2010.04167.x","article-title":"In vivo manipulation of V\u03b39V\u03b42 T cells with zoledronate and low-dose interleukin-2 for immunotherapy of advanced breast cancer patients","volume":"161","author":"Meraviglia","year":"2010","journal-title":"Clin Exp Immunol"},{"key":"B61","doi-asserted-by":"publisher","first-page":"1521","DOI":"10.1007\/s00262-010-0879-0","article-title":"Phase I study of bromohydrin pyrophosphate (BrHPP, IPH 1101), a V\u03b39V\u03b42 T lymphocyte agonist in patients with solid tumors","volume":"59","author":"Bennouna","year":"2010","journal-title":"Cancer Immunol Immunother"},{"key":"B62","doi-asserted-by":"publisher","first-page":"4875","DOI":"10.1182\/blood-2008-08-172296","article-title":"Bromohydrin pyrophosphate enhances antibody-dependent cell-mediated cytotoxicity induced by therapeutic antibodies","volume":"113","author":"Gertner-Dardenne","year":"2009","journal-title":"Blood"},{"key":"B63","doi-asserted-by":"publisher","first-page":"1447","DOI":"10.1007\/s00262-011-1049-8","article-title":"Pilot trial of interleukin-2 and zoledronic acid to augment \u03b3\u03b4T cells as treatment for patients with refractory renal cell carcinoma","volume":"60","author":"Lang","year":"2011","journal-title":"Cancer Immunol Immunother"},{"key":"B64","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1097\/CJI.0b013e318245bb1e","article-title":"Tumor-promoting versus tumor-antagonizing roles of \u03b3\u03b4T cells in cancer immunotherapy: results from a prospective phase I\/II trial","volume":"35","author":"Kunzmann","year":"2012","journal-title":"J Immunother"},{"key":"B65","doi-asserted-by":"publisher","first-page":"e4909","DOI":"10.1097\/MD.0000000000004909","article-title":"In vivo expansion and activation of \u03b3\u03b4 T cells as immunotherapy for refractory neuroblastoma: a phase 1 study","volume":"95","author":"Pressey","year":"2016","journal-title":"Medicine (Baltimore)"},{"key":"B66","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1007\/s00262-006-0199-6","article-title":"Safety profile and anti-tumor effects of adoptive immunotherapy using \u03b3\u03b4 T cells against advanced renal cell carcinoma: a pilot study","volume":"56","author":"Kobayashi","year":"2007","journal-title":"Cancer Immunol Immunother"},{"key":"B67","doi-asserted-by":"publisher","first-page":"1075","DOI":"10.1007\/s00262-011-1021-7","article-title":"Phase I\/II study of adoptive transfer of \u03b3\u03b4 T cells in combination with zoledronic acid and IL-2 to patients with advanced renal cell carcinoma","volume":"60","author":"Kobayashi","year":"2011","journal-title":"Cancer Immunol Immunother"},{"key":"B68","doi-asserted-by":"publisher","first-page":"778","DOI":"10.1038\/bjc.2011.293","article-title":"Clinical evaluation of autologous \u03b3\u03b4T cell-based immunotherapy for metastatic solid tumours","volume":"105","author":"Nicol","year":"2011","journal-title":"Br J Cancer"},{"key":"B69","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1186\/1479-5876-12-45","article-title":"Successful adoptive transfer and in vivo expansion of haploidentical \u03b3\u03b4 T cells","volume":"12","author":"Wilhelm","year":"2014","journal-title":"J Transl Med"},{"key":"B70","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1002\/cam4.196","article-title":"Intraperitoneal injection of in vitro expanded V\u03b39V\u03b42 T cells together with zoledronate for the treatment of malignant ascites due to gastric cancer","volume":"3","author":"Wada","year":"2014","journal-title":"Cancer Med"},{"key":"B71","doi-asserted-by":"publisher","first-page":"956","DOI":"10.1016\/j.exphem.2009.04.008","article-title":"Clinical and immunological evaluation of zoledronate-activated V\u03b39 \u03b3\u03b4 T-cell-based immunotherapy for patients with multiple myeloma","volume":"37","author":"Abe","year":"2009","journal-title":"Exp Hematol"},{"key":"B72","doi-asserted-by":"publisher","first-page":"1599","DOI":"10.1007\/s00262-008-0491-8","article-title":"Phase-I study of innacell \u03b3\u03b4, an autologous cell-therapy product highly enriched in \u03b39\u03b42 T lymphocytes, in combination with IL-2, in patients with metastatic renal cell carcinoma","volume":"57","author":"Bennouna","year":"2008","journal-title":"Cancer Immunol Immunother"},{"key":"B73","doi-asserted-by":"publisher","first-page":"1191","DOI":"10.1016\/j.ejcts.2009.11.051","article-title":"A phase I study of adoptive immunotherapy for recurrent non-small-cell lung cancer patients with autologous \u03b3\u03b4 T cells","volume":"37","author":"Nakajima","year":"2010","journal-title":"Eur J Cardiothorac Surg"},{"key":"B74","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1097\/CJI.0b013e318207ecfb","article-title":"Adoptive immunotherapy for advanced non-small cell lung cancer using zoledronate-expanded \u03b3\u03b4 T cells: a phase I clinical study","volume":"34","author":"Sakamoto","year":"2011","journal-title":"J Immunother"},{"key":"B75","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1038\/cmi.2012.39","article-title":"What lessons can be learned from \u03b3\u03b4 T cell-based cancer immunotherapy trials?","volume":"10","author":"Fourni\u00e9","year":"2012","journal-title":"Cell Mol Immunol"},{"key":"B76","doi-asserted-by":"publisher","first-page":"e643","DOI":"10.3389\/fimmu.2014.00643","article-title":"Monitoring circulating \u03b3\u03b4 T cells in cancer patients to optimize \u03b3\u03b4 T cell-based immunotherapy","volume":"5","author":"Oberg","year":"2014","journal-title":"Front Immunol"},{"key":"B77","doi-asserted-by":"publisher","first-page":"1349","DOI":"10.1158\/0008-5472.CAN-13-0675","article-title":"Novel bispecific antibodies increase \u03b3\u03b4 T-cell cytotoxicity against pancreatic cancer cells","volume":"74","author":"Oberg","year":"2014","journal-title":"Cancer Res"},{"key":"B78","doi-asserted-by":"publisher","first-page":"e0149570","DOI":"10.1371\/journal.pone.0149570","article-title":"Skewed differentiation of circulating V\u03b39V\u03b42 T lymphocytes in melanoma and impact on clinical outcome","volume":"11","author":"Toia","year":"2016","journal-title":"PLoS One"},{"key":"B79","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1002\/jbmr.1797","article-title":"Monocytes and \u03b3\u03b4 T cells control the acute-phase response to intravenous zoledronate: insights from a phase IV safety trial","volume":"28","author":"Welton","year":"2013","journal-title":"J Bone Miner Res"},{"key":"B80","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1007\/s00223-012-9647-9","article-title":"Long-term effects of amino-bisphosphonates on circulating \u03b3\u03b4 T cells","volume":"91","author":"Rossini","year":"2012","journal-title":"Calcif Tissue Int"},{"key":"B81","doi-asserted-by":"publisher","first-page":"2335","DOI":"10.1007\/s00018-013-1495-x","article-title":"Neutrophil uptake of nitrogen-bisphosphonates leads to the suppression of human peripheral blood \u03b3\u03b4 T cells","volume":"71","author":"Kalyan","year":"2014","journal-title":"Cell Mol Life Sci"},{"key":"B82","doi-asserted-by":"publisher","first-page":"3271","DOI":"10.1182\/blood-2012-03-417519","article-title":"Dysfunctional V\u03b39V\u03b42 T cells are negative prognosticators and markers of dysregulated mevalonate pathway activity in chronic lymphocytic leukemia cells","volume":"120","author":"Coscia","year":"2012","journal-title":"Blood"},{"key":"B83","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1016\/S1470-2045(11)70122-X","article-title":"Adjuvant endocrine therapy plus zoledronic acid in premenopausal women with early-stage breast cancer: 62-month follow-up from the ABCSG-12 randomised trial","volume":"12","author":"Gnant","year":"2011","journal-title":"Lancet Oncol"},{"key":"B84","doi-asserted-by":"publisher","first-page":"1989","DOI":"10.1016\/S0140-6736(10)62051-X","article-title":"First-line treatment with zoledronic acid as compared with clodronic acid in multiple myeloma (MRC Myeloma IX): a randomised controlled trial","volume":"376","author":"Morgan","year":"2010","journal-title":"Lancet"},{"key":"B85","doi-asserted-by":"publisher","first-page":"93179","DOI":"10.1172\/jci.insight.93179","article-title":"Adoptively transferred V\u03b39V\u03b42 T cells show potent antitumor effects in a preclinical B cell lymphomagenesis model","volume":"2","author":"Zumwalde","year":"2017","journal-title":"JCI Insight"},{"key":"B86","doi-asserted-by":"publisher","first-page":"6680","DOI":"10.4049\/jimmunol.1000681","article-title":"Phosphoantigens overcome human TCRV\u03b39+ \u03b3\u03b4 cell immunosuppression by TGF-\u03b2: relevance for cancer immunotherapy","volume":"184","author":"Capietto","year":"2010","journal-title":"J Immunol"},{"key":"B87","doi-asserted-by":"publisher","first-page":"400","DOI":"10.1158\/2326-6066","article-title":"IFN-\u03b3-dependent interactions between ICAM-1 and LFA-1 counteract prostaglandin E2-mediated Inhibition of antitumor CTL responses","volume":"4","author":"Basingab","year":"2016","journal-title":"Cancer Immunol Res"},{"key":"B88","doi-asserted-by":"publisher","first-page":"5427","DOI":"10.1158\/1078-0432","article-title":"Molecular pathways: targeting IDO1 and other tryptophan dioxygenases for cancer immunotherapy","volume":"21","author":"Zhai","year":"2015","journal-title":"Clin Cancer Res"},{"key":"B89","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1038\/nature19364","article-title":"Ionic immune suppression within the tumour microenvironment limits T cell effector function","volume":"537","author":"Eil","year":"2016","journal-title":"Nature"},{"key":"B90","doi-asserted-by":"publisher","first-page":"92","DOI":"10.3109\/14653249.2010.515581","article-title":"Zoledronate-activated V\u03b39 \u03b3\u03b4T cell-based immunotherapy is feasible and restores the impairment of \u03b3\u03b4 T cells in patients with solid tumors","volume":"13","author":"Noguchi","year":"2011","journal-title":"Cytotherapy"},{"key":"B91","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1016\/j.jcyt.2012.12.004","article-title":"Ex vivo characterization of \u03b3\u03b4 T-cell repertoire in patients after adoptive transfer of V\u03b39V\u03b42 T cells expressing the interleukin-2 receptor \u03b2-chain and the common \u03b3-chain","volume":"15","author":"Izumi","year":"2013","journal-title":"Cytotherapy"},{"key":"B92","doi-asserted-by":"publisher","first-page":"1346","DOI":"10.4049\/jimmunol.1300603","article-title":"Essential requirements of zoledronate-induced cytokine and T cell proliferative responses","volume":"191","author":"Nussbaumer","year":"2013","journal-title":"J Immunol"},{"key":"B93","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1007\/s00262-012-1368-4","article-title":"Zoledronic acid-induced expansion of \u03b3\u03b4 T cells from early-stage breast cancer patients: effect of IL-18 on helper NK cells","volume":"62","author":"Sugie","year":"2013","journal-title":"Cancer Immunol Immunother"},{"key":"B94","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1111\/liv.12011","article-title":"The activity of \u03b3\u03b4 T cells against paediatric liver tumour cells and spheroids in cell culture","volume":"33","author":"Hoh","year":"2013","journal-title":"Liver Int"},{"key":"B95","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/j.cellimm.2015.04.009","article-title":"\u03b3\u03b4 T cell activation by bispecific antibodies","volume":"296","author":"Oberg","year":"2015","journal-title":"Cell Immunol"},{"key":"B96","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1016\/j.canlet.2013.07.036","article-title":"A novel antibody-like TCR \u03b3\u03b4-Ig fusion protein exhibits antitumor activity against human ovarian carcinoma","volume":"341","author":"Zheng","year":"2013","journal-title":"Cancer Lett"},{"key":"B97","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1111\/sji.12581","article-title":"CD20-specific immunoligands engaging NKG2D enhance \u03b3\u03b4 T cell-mediated lysis of lymphoma cells","volume":"86","author":"Peipp","year":"2017","journal-title":"Scand J Immunol"},{"key":"B98","doi-asserted-by":"publisher","first-page":"2625","DOI":"10.1182\/blood-2013-11-492231","article-title":"Antibody-modified T cells: CARs take the front seat for hematologic malignancies","volume":"123","author":"Maus","year":"2014","journal-title":"Blood"},{"key":"B99","doi-asserted-by":"publisher","first-page":"638","DOI":"10.1038\/mt.2012.267","article-title":"Bispecific T-cells expressing polyclonal repertoire of endogenous \u03b3\u03b4 T-cell receptors and introduced CD19-specific chimeric antigen receptor","volume":"21","author":"Deniger","year":"2013","journal-title":"Mol Ther"},{"key":"B100","doi-asserted-by":"publisher","first-page":"928","DOI":"10.1038\/nbt.2678","article-title":"Generation of tumor-targeted human T lymphocytes from induced pluripotent stem cells for cancer therapy","volume":"31","author":"Themeli","year":"2013","journal-title":"Nat Biotechnol"},{"key":"B101","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1126\/science.1129003","article-title":"Cancer regression in patients after transfer of genetically engineered lymphocytes","volume":"314","author":"Morgan","year":"2006","journal-title":"Science"},{"key":"B102","doi-asserted-by":"publisher","first-page":"10972","DOI":"10.1073\/pnas.1005802107","article-title":"Mixed T cell receptor dimers harbour potentially harmful neoreactivity","volume":"107","author":"Van Loenen","year":"2010","journal-title":"Proc Natl Acad Sci U S A"},{"key":"B103","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1038\/nm.2128","article-title":"Lethal graft-versus-host disease in mouse models of T cell receptor gene therapy","volume":"16","author":"Bendle","year":"2010","journal-title":"Nat Med"},{"key":"B104","doi-asserted-by":"publisher","first-page":"3331","DOI":"10.1158\/0008-5472.CAN-05-4190","article-title":"\u03b1\u03b2 T-cell receptor engineered \u03b3\u03b4 T cells mediate effective anti-leukemic reactivity","volume":"66","author":"Van der Veken","year":"2006","journal-title":"Cancer Res"},{"key":"B105","doi-asserted-by":"publisher","first-page":"164","DOI":"10.4049\/jimmunol.182.1.92","article-title":"\u03b1\u03b2 T cell receptor transfer to \u03b3\u03b4 T cells generates functional effector cells without mixed TCR dimers in vivo","volume":"182","author":"Van der Veken","year":"2009","journal-title":"J Immunol"},{"key":"B106","doi-asserted-by":"publisher","first-page":"620","DOI":"10.1038\/gt.2009.6","article-title":"Rapid \u03b1\u03b2 TCR-mediated responses in \u03b3\u03b4 T cells transduced with cancer-specific TCR genes","volume":"16","author":"Hiasa","year":"2009","journal-title":"Gene Ther"},{"key":"B107","doi-asserted-by":"publisher","first-page":"e22590","DOI":"10.4161\/onci.22590","article-title":"Human MHC class I-restricted high avidity CD4+ T cells generated by co-transfer of TCR and CD8 mediate efficient tumor rejection in vivo","volume":"2","author":"Xue","year":"2013","journal-title":"Oncoimmunology"},{"key":"B108","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1111\/cei.12570","article-title":"TCR binding affinity governs the functional profile of cancer-specific CD8+ T cells","volume":"180","author":"Tan","year":"2014","journal-title":"Clin Exp Immunol"},{"key":"B109","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1182\/blood-2010-12-325993","article-title":"Redirecting \u03b1\u03b2 T cells against cancer cells by transfer of a broadly tumor-reactive \u03b3\u03b4 T-cell receptor","volume":"118","author":"Marcu-Malina","year":"2011","journal-title":"Blood"},{"key":"B110","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1038\/cmi.2011.28","article-title":"CDR3\u03b4-grafted \u03b39\u03b42 T cells mediate effective antitumor reactivity","volume":"9","author":"Zhao","year":"2012","journal-title":"Cell Mol Immunol"},{"key":"B111","doi-asserted-by":"publisher","first-page":"e992749","DOI":"10.4161\/2162402X.2014.992749","article-title":"Ex vivo expanded human circulating V\u03b41 \u03b3\u03b4 T cells exhibit favourable therapeutic potential for colon cancer","volume":"4","author":"Wu","year":"2015","journal-title":"Oncoimmunology"},{"key":"B112","doi-asserted-by":"publisher","first-page":"5795","DOI":"10.1158\/1078-0432.CCR-16-0597","article-title":"Delta one T cells for immunotherapy of chronic lymphocytic leukemia: clinical-grade expansion\/differentiation and preclinical proof of concept","volume":"22","author":"Almeida","year":"2016","journal-title":"Clin Cancer Res"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"http:\/\/journal.frontiersin.org\/article\/10.3389\/fimmu.2017.01401\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,8,5]],"date-time":"2022-08-05T17:36:23Z","timestamp":1659720983000},"score":1,"resource":{"primary":{"URL":"http:\/\/journal.frontiersin.org\/article\/10.3389\/fimmu.2017.01401\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,10,27]]},"references-count":112,"alternative-id":["10.3389\/fimmu.2017.01401"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2017.01401","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,10,27]]},"article-number":"1401"}}